Issue of Equity

RNS Number : 7576C

HeiQ PLC

24 February 2022

 

24 February 2022

HeiQ Plc

("HeiQ" or "the Company")

Issue of Equity and Total Voting Rights

HeiQ Plc (LSE: HEIQ), a Swiss IP innovator and established global brand in materials and textile innovation which operates in high-growth markets, announces the issuance of 347,552 new ordinary shares of £0.30 each in the Company ("New Shares"). These shares have been allotted to the vendors of Life Material Technologies Limited ("Life") to satisfy a closing working capital adjustment in connection with the Company's acquisition of Life in June 2021, further details of which are contained within the Company's announcement dated 15 June 2021. As previously announced, additional earn-out consideration may be payable to Life in due course through the issuance of new ordinary shares and a further announcement will be made in due course.

Applications have been made to the London Stock Exchange and FCA for the New Shares to be admitted to the standard segment of the Official List and also admitted to trading on the London Stock Exchange ("Admisison").

Admission is expected to become effective on 25 February  2022.

The shares will be issued fully paid and will rank pari passu in all respects with the existing issued ordinary shares of the Company.

Total Voting Rights

Following the issue and allotment of the New Shares the Company has 130,931,088 Ordinary Shares in issue. The Company holds no Ordinary Shares in treasury, and therefore the total number of voting rights in the Company is 130,931,088. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

HeiQ Plc Carlo Centonze (CEO)	[phone]
Cenkos Securities plc (Joint Broker) Stephen Keys / Callum Davidson	[phone]
SEC Newgate (Media Enquiries) Elisabeth Cowell / Robin Tozer / Megan Kovach	[phone] HeiQ@s ecnewgate .co.uk

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibers market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

END

 

 

IOESEEFLLEESEIE